Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) posted quarterly EBITDA Margin of 212.99% for Q1 2025, up 15152.0% year-over-year from N/an in Q1 2024, and up 18.63% quarter-over-quarter from 261.76% in Q4 2024.
Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported EBITDA Margin for 7 consecutive years, with 212.99% the latest figure, recorded in Q1 2025.
- In Q1 2025, EBITDA Margin rose 15152.0% year-over-year to 212.99%; the TTM figure through Dec 2025 stood at 1601.12% (down 134150.0% YoY), while the FY2025 annual figure was 1601.12%, down 134150.0% from the prior year.
- EBITDA Margin rose to 212.99% in Q1 2025 per WHWK's latest filing, from 261.76% in the prior quarter.
- Across five years, EBITDA Margin topped out at 113.89% in Q4 2021 and bottomed at 3405.83% in Q1 2021.
- Historically, EBITDA Margin has averaged 517.45% across 5 years, with a median of 296.0% in 2022.
- On a YoY basis, EBITDA Margin climbed as much as 280705 bps in 2022 and fell as far as 18211 bps in 2022.
- Whitehawk Therapeutics' EBITDA Margin stood at 113.89% in 2021, then tumbled by 160 bps to 296.0% in 2022, then grew by 5 bps to 280.02% in 2023, then increased by 7 bps to 261.76% in 2024, then grew by 19 bps to 212.99% in 2025.
- Business Quant data shows WHWK's EBITDA Margin at 212.99% in Q1 2025, 261.76% in Q4 2024, and 185.98% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Whitehawk Therapeutics | 369.67 Mn | 74.92 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -212.99% |
| Dec 31, 2024 | -261.76% |
| Sep 30, 2024 | -185.98% |
| Jun 30, 2024 | -252.21% |
| Mar 31, 2024 | -364.51% |
| Dec 31, 2023 | -280.02% |
| Sep 30, 2023 | -299.53% |
| Jun 30, 2023 | -315.14% |
| Mar 31, 2023 | -286.77% |
| Dec 31, 2022 | -296.00% |
| Sep 30, 2022 | -354.20% |
| Jun 30, 2022 | -534.19% |
| Mar 31, 2022 | -598.79% |
| Dec 31, 2021 | -113.89% |
| Mar 31, 2021 | -3,405.83% |
| Dec 31, 2020 | 60.03% |
| Sep 30, 2020 | -1,152.81% |
| Jun 30, 2020 | 61.71% |
| Dec 31, 2018 | -413,534.42% |
| Sep 30, 2018 | 59.49% |